# AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

> **NCT00003759** · PHASE2 · COMPLETED · sponsor: **Anthra Pharmaceuticals**

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** BCG vaccine
- **DRUG:** valrubicin
- **PROCEDURE:** conventional surgery

## Key facts

- **NCT ID:** NCT00003759
- **Lead sponsor:** Anthra Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-11
- **Primary completion:** —
- **Final completion:** 2002-11
- **Target enrollment:** — (—)
- **Last updated:** 2013-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003759

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003759, "AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00003759. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*